Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaufman, J
Right arrow Articles by Schlueter, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kaufman, J
Right arrow Articles by Schlueter, D.

Chest, Vol 95, 544-548, Copyright © 1989 by American College of Chest Physicians

ARTICLES

Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors

J Kaufman, JE Casanova, P Riendl and DP Schlueter
Department of Medicine, Medical College of Wisconsin, Milwaukee.

Seventeen patients using angiotensin-converting enzyme (ACE) inhibitors for hypertension were evaluated with baseline spirometry followed by determination of bronchial reactivity by challenge with methacholine. There were nine coughers and eight noncoughers in the study. Among the nine coughers, eight demonstrated bronchial hyperreactivity. Conversely, none of the noncoughers disclosed bronchial hyperreactivity. Eight of the nine coughers were rechallenged two to six months following cessation of ACE inhibitor therapy. Six of these eight showed persistent bronchial hyperreactivity. We conclude that cough is associated with the use of ACE inhibitors in patients with underlying bronchial hyperreactivity. The findings indicate caution in administration of ACE inhibitors in asthmatic patients and those with known bronchial hyperreactivity.


This article has been cited by other articles:


Home page
 BMJHome page
H Lunde, T Hedner, O Samuelsson, J Lotvall, L Andren, L Lindhom, and B E Wilholm
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors
BMJ, January 1, 1994; 308(6920): 18 - 18.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Chest Physicians.